Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Don't know

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Aug 28, 2020 12:34am

112 Views

Post# 31468189

RE:RE:RE:RE:Don't know

Seems like the board has been taken over by a bunch of negative nanny's who can;t find anything worthwhile to do with their time. Hope they get a thrill out of it and that great feeling that they have really accomplished something.

Now that took 42 words - I could probably have summed it up in one or two but that would not be proper -- and you always have to be proper these days so as not to hurt somebodys feelings! Right luvhorseslinda? :-))

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023